01.08.2018 Meet ng L brary | B olog c markers gu d ng the treatment of non-small cell lung cancer: RRM-1, class III ß tubul n, and ERCC-1.
https://meet ngl brary.asco.org/record/84509/abstract 1/2
Biologic markers guiding the treatment of non-small cell lung cancer: RRM-1,
class III ß tubulin, and ERCC-1.
Authors:
Esat Namal, Mustafa Bozkurt, Akin Ozturk, Kezban Nur Planci, Nuray Bassullu, Ozgul Pamukcu, Gulen Bulbul Dogusoy, Sezer Saglam, Zafer Akcali, Gokhan Demir; Istanbul Bilim University, Department of Medical Oncology, Istanbul, Turkey; Medical Oncology Department, Istanbul Bilim University School of Medicine, Istanbul, Turkey; Istanbul Bilim University, Medical Faculty, Department of Medical Oncology, Istanbul, Turkey; Istanbul Bilim University, Medical Faculty, Department of Pathology, Istanbul, Turkey; Istanbul Sisli Etfal Training and Research Hospital, Istanbul, Turkey; Department of Medical Oncology, Medical School, Ufuk University, Ankara, Turkey; Istanbul Bilim University Faculty of Medicine,
Department of Medical Oncology, Istanbul, Turkey
View Less
Abstract Disclosures Background:
Lung cancer is the most common cause of cancer deaths in the world. Despite the developments in diagnosis and treatment, the high mortality rate in metastatic non small cell lung cancer (NSCLC) is still an important problem. Recent non-targeted standard therapy for NSCLC is the dual therapy regimens which involve platins. Our former knowledge whether these therapies can be e ective or not would save the patient from the redundant toxicity and provide us to use more e ective drugs formerly. Understanding the biology of NSCLC can allow choosing the e ective and appropriate therapy in terms of life quality, survival rate and relapses. There are ongoing studies upon prognostic and predictive values of ERCC1, RRM1 and β tubulin in NSCLC patients. In this study we aimed to investigate the role of β tubulin, ERCC1 and RRM1 expressions as predictive biomarkers.
Methods:
47 patients who are on follow up by Bilim University, Medical Oncology Department, were taken to the study. ß tubulin, ERCC1 and RRM1 over expressions were investigated in the biopsy materials of these patients by Pathology Department. Retrospectively, it was evaluated whether there is correlation between these biological markers and patients’ survial rates and responses to antineoplastic therapies.
01.08.2018 Meet ng L brary | B olog c markers gu d ng the treatment of non-small cell lung cancer: RRM-1, class III ß tubul n, and ERCC-1.
https://meet ngl brary.asco.org/record/84509/abstract 2/2
This content is made available for your personal use, educational advancement, or professional development. Unauthorized reproduction is prohibited. For permission to re-use for commercial or other purposes, please contact permissions@asco.org
Results:
In the literature, there are some studies which show that β tubulin score is a predictive marker for the good response to taxan therapy. On the other hand, it was shown that taxans enhance the platin sensitivity decreasing the β tubulin expressions. Our study was also correlated with these studies in the literature. Furthermore, there was relationship between the β tubulin score and age. 15 patients (%32) were 65 or under 65 and these were accepted as ‘young patient population’; 32 patients were over 65 and were accepted as ‘old patient population’. Most of the patients whose β tubulin score was high (n=29), were young (n=19); and most of the patients whose β tubulin score was low (n=18) were old patients (n=12) (p=0.032).
Conclusions:
Detecting the levels of β tubulin, ERCC1 and RRM1 before treatment in NSCLC patients, can be predictive to organize the treatment. Unquestionably, it must be supported by the studies involve more patients.
